This roundup collects five peer-reviewed papers indexed in PubMed during August and September 2026 that touch compounds and mechanisms researchers ask us about. Each summary is drawn from the paper's published abstract, and each links to the original source. The aim is to report what was tested and in which model, not to extrapolate beyond it.
Cerberus Research Labs supplies compounds strictly for laboratory research use. Nothing here is dosing guidance, medical advice, or a therapeutic claim, and findings from animal or cell models should not be read as applying to people.
1. Retatrutide plus cagrilintide: five-receptor pharmacology in obese rats
Source: Petersen et al., Nature Metabolism, September 2026 (doi:10.1038/s42255-026-01603-y).
The authors co-administered retatrutide (a single-molecule GLP-1R/GIPR/glucagon-receptor tri-agonist) with cagrilintide (an amylin/calcitonin-receptor co-agonist) in diet-induced obese male rats. They report dose-dependent reductions in body weight and food intake that exceeded equimolar monotherapies and matched-dose comparator combinations built on semaglutide or tirzepatide, along with changes in circulating cholesterol, triglycerides and insulin.
The methodologically interesting part is the controls. Pair-feeding and weight-matching arms were used to separate effects that follow from eating less from effects specific to the drug combination, and the authors report that reduced intake alone did not account for the difference. Plasma proteomics and brain transcriptomics were added to map the molecular response. The paper frames the result as support for "five-receptor polypharmacology" as a design direction for future single-molecule agonists. For background on both compounds, see our earlier pieces on retatrutide and cagrilintide.
2. Three incretin agonists compared in kidney-fibrosis models
Source: Ding et al., iScience, August 2026 (doi:10.1016/j.isci.2026.117174).
This study compared semaglutide, tirzepatide and retatrutide in non-diabetic renal fibrosis, using HK-2 kidney cells, a mouse unilateral ureteral obstruction (UUO) model and an aged-mouse model. The headline is that the three agents showed model- and drug-specific pathway signatures rather than one shared mechanism: in the UUO model, the semaglutide response was associated with PI3K-AKT inhibition, tirzepatide with PI3K-AKT inhibition plus PPAR pathway activation, and retatrutide with inhibition of both PI3K-AKT and NF-kappaB signaling. The authors note retatrutide showed the greatest effect at the doses tested in these models, and describe the work as hypothesis-generating.
3. Tirzepatide in a nicotine-reward model
Source: Edvardsson et al., British Journal of Pharmacology, September 2026 (doi:10.1111/bph.70678).
Incretin signaling has been studied for some time in reward-circuit research. Here the authors asked whether tirzepatide, a dual GIP/GLP-1 receptor agonist, alters nicotine-induced behaviors in male mice. They report that it attenuated nicotine-induced locomotor stimulation, reduced conditioned place preference and its reinstatement, prevented expression of locomotor sensitization, and blunted nicotine-induced dopamine release in the nucleus accumbens measured by in vivo microdialysis. Ex vivo analysis also showed region-specific changes in other neurotransmitter systems, including GABA, which the authors suggest points to effects beyond dopamine alone. This is a behavioral pharmacology result in mice and is reported as such.
4. MOTS-c: a hydrogel study and a candid review
Sources: Li et al., Bioactive Materials, August 2026 (doi:10.1016/j.bioactmat.2026.06.010); Zhao et al., European Journal of Pharmacology, August 2026 (doi:10.1016/j.ejphar.2026.179261).
Two papers on the mitochondria-derived peptide MOTS-c are worth reading together. In the first, a materials-science group conjugated MOTS-c to a self-assembling peptide (Q11) to build a hydrogel carrier for isolated mitochondria. They report that the hydrogel extended the functional survival of isolated mitochondria in vitro, increased mitochondrial uptake by macrophages through an AMPK-dependent mechanism, and shifted macrophage metabolism away from glycolysis toward oxidative phosphorylation. In a rat myocardial-infarction model, the system was associated with reduced pro-inflammatory macrophage infiltration and less cardiomyocyte damage.
The second is a review of MOTS-c in sepsis-induced cardiomyopathy, and it is notable for its restraint. The authors separate direct disease-specific evidence from findings extrapolated from other cardiovascular, metabolic and inflammatory models, and conclude that MOTS-c is "plausible but insufficiently validated" in that setting. It is a useful reminder that a compelling mechanism in one model is not evidence in another.
5. GHK-Cu: what a systematic review actually found
Source: Mokhtar et al., Aesthetic Surgery Journal, August 2026 (doi:10.1093/asj/sjag169).
This PRISMA-guided systematic review searched PubMed, Embase and Cochrane CENTRAL through March 2026 and included 20 studies on the copper peptide GHK-Cu, of which 18 were preclinical and 2 were randomized controlled trials. In the preclinical literature the authors describe consistent effects on extracellular-matrix synthesis (type I collagen and glycosaminoglycans), metalloproteinase activity, angiogenesis and inflammatory signaling (TGF-beta and IL-6), and note that delivery systems such as microneedles and liposomes were studied as ways to improve transdermal delivery.
The more important line is the limitation the authors state themselves: findings were constrained by methodological variability and few well-designed clinical trials, and they call for larger controlled studies with standardized formulations. The evidence base, in other words, is still mostly preclinical. Our GHK-Cu research overview covers the underlying biology in more depth.
Reading the week's papers
- Check the model. Four of the five items are rodent or cell studies. Species, sex (several used male animals only) and disease model all limit how far a result travels.
- Look for the control that matters. The pair-feeding arms in the retatrutide-cagrilintide paper are what make its mechanistic claim testable.
- Weigh reviews by their inclusion counts. Twenty studies sounds substantial until you see that eighteen are preclinical.
Research use only. Not for human use. Not for veterinary use. Nothing on this page is medical advice, and summaries of published research are not claims of safety, efficacy or suitability for any purpose outside laboratory research.
For your own bench work
Compounds discussed above are listed in the research catalog, each with lot-specific certificates of analysis in the documentation hub. For stock-solution arithmetic, use the peptide reconstitution calculator.